Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Bone Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Allogeneic Osteoblastic Cells

            Therapeutic Area: Musculoskeletal Product Name: Allob

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 12, 2021

            Details:

            The ALLOB Tibial Fracture Phase IIb study is a randomized, double-blind, placebo-controlled study. In this study, the potential of ALLOB to accelerate fracture healing and prevent late-stage complications in patients with difficult fractures in the shinbone (tibia).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JTA-004

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 22, 2020

            Details:

            JTA-004 is unique patented mix of plasma proteins, hyaluronic acid, and a fast-acting analgesic. Bone Therapeutics has completed recruitment and treated all patients in its pivotal Phase III clinical study with the improved viscosupplement in patients with knee osteoarthritis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALLOB

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Catalent Pharma Solutions

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition November 16, 2020

            Details:

            Catalent has purchased the shares of SCTS and a purpose-built CGxP facility of approximately 41,000 square-foot. Catalent will undertake the manufacturing of clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy product.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALLOB

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Catalent Pharma Solutions

            Deal Size: $14.2 million Upfront Cash: Undisclosed

            Deal Type: Acquisition October 30, 2020

            Details:

            Agreements will streamline and economize the manufacturing operations of ALLOB, Bone Therapeutics’ allogeneic cell therapy product and will enable Bone Therapeutics to focus on the development of products from its differentiated MSC platform of cell and gene therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JTA-004

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 20, 2020

            Details:

            The JTA-004 Phase III study is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading current osteoarthritis treatment on the market.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALLOB

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            The 24 month follow-up data of this Phase IIa clinical trial have shown that patients treated with ALLOB in spinal fusion procedure show a high incidence in fusion, and benefit from a sustained, clinically meaningful improvement in function and pain throughout the 24 months.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JTA-004

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $1.1 million Upfront Cash: Undisclosed

            Deal Type: Funding August 13, 2020

            Details:

            Funding will provide further financial support to Bone Therapeutics, in addition to recent financing, to advance its current pivotal phase III clinical study with the enriched protein solution, JTA-004.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hyaluronic Acid,Plasma proteins,Fast-acting analgesic

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            Details:

            The JTA-004 phase III study is a controlled, randomized, double-blind trial that will evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20.